Cardiac imaging in cardiotoxicity: a focus on clinical practice.

Antineoplastic Agents / adverse effects Cardiotoxicity / diagnostic imaging Early Detection of Cancer Echocardiography Heart Heart Diseases / diagnosis Humans Ventricular Dysfunction, Left
Cardiac imaging Cardiac magnetic resonance Cardiotoxicity Global longitudinal strain Three dimensional echocardiography

Journal

Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 20 4 2020
medline: 15 12 2021
entrez: 20 4 2020
Statut: ppublish

Résumé

Cancer therapeutics induced cardiotoxicity has emerged as an important factor of long-term adverse cardiovascular outcomes in survivors of various malignant diseases. Early detection of myocardial injury in the setting of cancer treatment is important for the initiation of targeted cardioprotective therapy, in order to prevent irreversible cardiac dysfunction and heart failure, while not withholding a potentially life-saving cancer therapy. Cardiac imaging techniques including echocardiography, cardiac magnetic resonance, and nuclear cardiac imaging are the main tools for the identification of cardiotoxicity. There is also growing evidence for the detection of subclinical cardiac dysfunction in cancer patients by speckle tracking echocardiography. In this review article, we focus on current and emerging data regarding the role of cardiac imaging for the detection of changes in myocardial function related with cancer treatment in clinical practice.

Identifiants

DOI: 10.1007/s10741-020-09952-w PMID: 32306221
pubmed: 32306221
doi: 10.1007/s10741-020-09952-w
pii: 10.1007/s10741-020-09952-w
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1175-1187

Informations de copyright

© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics. CA Cancer J Clin. 66:271–289
pubmed: 27253694 doi: 10.3322/caac.21349 pmcid: 27253694
Mavrogeni SI, Sfendouraki E, Markousis-Mavrogenis G, Rigopoulos A, Noutsias M, Kolovou G, Angeli C, Tousoulis D (2019) Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors. Heart Fail Rev 24:977–987
pubmed: 31134427 doi: 10.1007/s10741-019-09805-1 pmcid: 31134427
Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12:62
Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 37:2768–2801
doi: 10.1093/eurheartj/ehw211
Abdel-Qadir H, Austin PC, Lee DS et al (2017) A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol 2:88–93
pubmed: 27732702 doi: 10.1001/jamacardio.2016.3841 pmcid: 27732702
Armstrong GT, Oeffinger KC, Chen Y et al (2013) Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31:3673–3680
pubmed: 24002505 pmcid: 3804290 doi: 10.1200/JCO.2013.49.3205
Westphal JG, Rigopoulos AG, Bakogiannis C, Ludwig SE, Mavrogeni S, Bigalke B, Doenst T, Pauschinger M, Tschope C, Schulze PC, Noutsias M (2017) The MOGE(S) classification for cardiomyopathies: current status and future outlook. Heart Fail Rev 22(6):743–752
pubmed: 28721466 doi: 10.1007/s10741-017-9641-4 pmcid: 28721466
Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755–1764
pubmed: 29567210 pmcid: 6196725 doi: 10.1016/j.jacc.2018.02.037
Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the ASE and the EACVI. J Am Soc Echocardiogr. 27:911–939
pubmed: 25172399 doi: 10.1016/j.echo.2014.07.012 pmcid: 25172399
Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981–1988
pubmed: 25948538 doi: 10.1161/CIRCULATIONAHA.114.013777 pmcid: 25948538
Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900–2902
pubmed: 15860848 doi: 10.1200/JCO.2005.05.827 pmcid: 15860848
Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G (2015) Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 94:228–237
pubmed: 25577572 doi: 10.1016/j.critrevonc.2014.12.008 pmcid: 25577572
Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ (2014) Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer 50:2162–2170
pubmed: 24930624 doi: 10.1016/j.ejca.2014.05.013 pmcid: 24930624
Khouri MG, Douglas PS, Mackey JR et al (2012) Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 126:2749–2763
pubmed: 3667651 pmcid: 3667651 doi: 10.1161/CIRCULATIONAHA.112.100560
Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the ASE and the EACVI. J Am Soc Echocardiogr. 28:1–39
pubmed: 25559473 doi: 10.1016/j.echo.2014.10.003 pmcid: 25559473
Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH (2013) Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 61:77–84
pubmed: 23199515 doi: 10.1016/j.jacc.2012.09.035 pmcid: 23199515
Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH (2009) Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J 30:98–106
pubmed: 18997179 doi: 10.1093/eurheartj/ehn484 pmcid: 18997179
Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE (2012) Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol. 59(20):1799–1808
pubmed: 22575319 pmcid: 3773600 doi: 10.1016/j.jacc.2012.01.037
Toro-Salazar OH, Ferranti J, Lorenzoni R et al (2016) Feasibility of echocardiographic techniques to detect subclinical cancer therapeutics-related cardiac dysfunction among high-dose patients when compared with cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 29:119–131
pubmed: 26678319 doi: 10.1016/j.echo.2015.10.008 pmcid: 26678319
Mor-Avi V, Lang RM (2013) Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Coll Cardiol 61:85–87
pubmed: 23199517 doi: 10.1016/j.jacc.2012.10.006 pmcid: 23199517
Tsang W, Salgo IS, Medvedofsky D et al (2016) Transthoracic 3D echocardiographic left heart chamber quantification using an automated adaptive analytics algorithm. J Am Coll Cardiol Imaging 9:769–782
doi: 10.1016/j.jcmg.2015.12.020
Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879
pubmed: 12767102 doi: 10.1002/cncr.11407 pmcid: 12767102
Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213–220
pubmed: 20117401 pmcid: 20117401 doi: 10.1016/j.jacc.2009.03.095
Eidem BW (2008) Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough. J Am Soc Echocardiogr 21:1290–1292
pubmed: 19041570 doi: 10.1016/j.echo.2008.10.008 pmcid: 19041570
Ohtani K, Ide T, Hiasa KI, Sakamoto I, Yamashita N, Kubo M, Tsutsui H (2019) Cardioprotective effect of renin–angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol. 108(10):1128–1139
pubmed: 30859381 doi: 10.1007/s00392-019-01448-4 pmcid: 30859381
Ohtani K, Fujino T, Ide T, Funakoshi K, Sakamoto I, Hiasa KI, Higo T, Kamezaki K, Akashi K, Tsutsui H (2019) Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. Clin Res Cardiol. 108(6):600–611
pubmed: 30367208 doi: 10.1007/s00392-018-1386-0 pmcid: 30367208
Mor-Avi V, Lang RM, Badano LP et al (2011) Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the japanese society of echocardiography. J Am Soc Echocardiogr. 24:277–313
pubmed: 21338865 doi: 10.1016/j.echo.2011.01.015 pmcid: 21338865
Ikonomidis I, Makavos G, Papadavid E et al (2015) Similarities in coronary function and myocardial deformation between psoriasis and coronary artery disease: the role of oxidative stress and inflammation. Can J Cardiol 31:287–295
pubmed: 25660150 doi: 10.1016/j.cjca.2014.11.002 pmcid: 25660150
Phelan D, Collier P, Thavendiranathan P et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 98(19):1442–1448
pubmed: 22865865 doi: 10.1136/heartjnl-2012-302353 pmcid: 22865865
Ikonomidis I, Tzortzis S, Lekakis J et al (2009) Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 95(18):1502–1507
pubmed: 19482847 doi: 10.1136/hrt.2009.168971 pmcid: 19482847
Paraskevaidis IA, Ikonomidis I, Simitsis P, Parissis J, Stasinos V, Makavos G, Lekakis J (2017) Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study. Eur J Heart Fail. 19(7):846–861
pubmed: 28220640 doi: 10.1002/ejhf.787 pmcid: 28220640
Stoodley PW, Richards DA, Hui R et al (2011) Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr 12:945–952
pubmed: 21965152 doi: 10.1093/ejechocard/jer187 pmcid: 21965152
Florescu M, Magda LS, Enescu OA, Jinga D, Vinereanu D (2014) Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr 27:83–92
pubmed: 24268372 doi: 10.1016/j.echo.2013.10.008 pmcid: 24268372
Poterucha JT, Kutty S, Lindquist RK, Li L, Eidem BW (2012) Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. J Am Soc Echocardiogr 25:733–740
pubmed: 22578518 doi: 10.1016/j.echo.2012.04.007 pmcid: 22578518
Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH (2013) Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26:493–498
pubmed: 23562088 doi: 10.1016/j.echo.2013.02.008 pmcid: 23562088
Paraskevaidis IA, Makavos G, Tsirigotis P et al (2017) Deformation analysis of myocardial layers detects early cardiac dysfunction after chemotherapy in bone marrow transplantation patients: a continuous and additive cardiotoxicity process. J Am Soc Echocardiogr. 30:1091–1102
pubmed: 28864152 doi: 10.1016/j.echo.2017.07.010 pmcid: 28864152
Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH (2014) Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 15:324–331
pubmed: 24057661 pmcid: 24057661 doi: 10.1093/ehjci/jet159
Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH (2013) Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr. 26:185–191
pubmed: 23218891 doi: 10.1016/j.echo.2012.10.008 pmcid: 23218891
Farsalinos KE, Daraban AM, Unlu S, Thomas JD, Badano LP, Voigt JU (2015) Head-to-head comparison of global longitudinal strain measurements among nine different vendors. The EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr 28:1171–1181
pubmed: 26209911 doi: 10.1016/j.echo.2015.06.011 pmcid: 26209911
Voigt J, Pedrizzetti G, Lysyansky P et al (2015) Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 16:1–11
pubmed: 25525063 doi: 10.1093/ehjci/jeu184 pmcid: 25525063
Yang H, Marwick TH, Fukuda N et al (2015) Improvement in strain concordance between two major vendors after the strain standardization initiative. J Am Soc Echocardiogr. 28:642–648
pubmed: 25636366 doi: 10.1016/j.echo.2014.12.009 pmcid: 25636366
Negareh M, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M (2015) Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50–59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 16:977–984
Narayan HK, French B, Khan AM et al (2016) Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction. JACC Cardiovasc Imaging. 9:1131–1141
pubmed: 27085442 pmcid: 5055405 doi: 10.1016/j.jcmg.2015.11.024
Laufer-Perl M, Arnold JH, Mor L, Amrami N, Derakhshesh M, Moshkovits Y, Sadeh B, Arbel Y, Topilsky Y, Rozenbaum Z (2019) The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy. Clin Res Cardiol. 109(2):255–262
pubmed: 31214777 doi: 10.1007/s00392-019-01508-9 pmcid: 31214777
Armenian SH, Hudson MM, Mulder RL et al (2015) International Late Effects of Childhood Cancer Guideline Harmonization Group. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:123–136
doi: 10.1016/S1470-2045(14)70409-7
Valbuena-Lop’ez S, Hinojar R, Puntmann VO (2016) Cardiovascular magnetic resonance in cardiology practice: a concise guide to image acquisition and clinical interpretation. Rev Esp Cardiol. 69:202–210
doi: 10.1016/j.recesp.2015.11.012
Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JA (2012) LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging 5:837–848
pubmed: 22897998 pmcid: 3501209 doi: 10.1016/j.jcmg.2012.06.003
Drafts BC, Twomley KM, D’Agostino R et al (2013) Low to moderate dose anthracycline based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 6:877–885
pubmed: 23643285 pmcid: 3745801 doi: 10.1016/j.jcmg.2012.11.017
Friedrich MG, Sechtem U, Schulz-Menger J et al (2009) International Consensus Group on Cardiovascular Magnetic Resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 53:1475–1487
pubmed: 19389557 pmcid: 2743893 doi: 10.1016/j.jacc.2009.02.007
Abdel-Aty H, Boye P, Zagrosek A et al (2005) Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 45:1815–1822
pubmed: 15936612 doi: 10.1016/j.jacc.2004.11.069 pmcid: 15936612
Kim RJ, Wu E, Rafael A et al (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 343:1445–1453
pubmed: 11078769 doi: 10.1056/NEJM200011163432003 pmcid: 11078769
Nakamori S, Dohi K, Ishida M et al (2018) Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. J Am Coll Cardiol Intv 11:48–59
doi: 10.1016/j.jcmg.2017.04.006
Kellman P, Wilson JR, Xue H et al (2012) Extracellular volume fraction mapping in the myocardium, part 2: Initial clinical experience. J Cardiovasc Magn Reson. 14:64
pubmed: 22967246 pmcid: 3442966 doi: 10.1186/1532-429X-14-64
Lightfoot JC, D’Agostino RB Jr, Hamilton CA et al (2010) Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging. 3:550–558
pubmed: 20622140 pmcid: 3068484 doi: 10.1161/CIRCIMAGING.109.918540
Thavendiranathan P, Walls M, Giri S et al (2012) Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping. Circ Cardiovasc Imaging. 5:102–110
pubmed: 22038988 doi: 10.1161/CIRCIMAGING.111.967836 pmcid: 22038988
Galán-Arriola C, Lobo M, Vílchez-Tschischke JP et al (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73:779–791
pubmed: 30784671 doi: 10.1016/j.jacc.2018.11.046 pmcid: 30784671
Neilan TG, Coelho-Filho OR, Pena-Herrera D et al (2012) Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 110:1679–1686
pubmed: 22917553 pmcid: 3496816 doi: 10.1016/j.amjcard.2012.07.040
Stamouli M, Gkirkas M, Antoniades A, Kaklamanis L, Gkodopoulos K, Palios J, Karagiannidou A, Makavos G, Ikonomidis I, Tsirigotis P (2019) Isolated extramedullary leukemic involvement of the heart presenting as fulminant heart failure. Ann Hematol 98(7):1775–1776
pubmed: 30859260 doi: 10.1007/s00277-019-03665-3 pmcid: 30859260
Neilan TG, Coelho-Filho OR, Shah RV et al (2013) Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 111:717–722
pubmed: 23228924 doi: 10.1016/j.amjcard.2012.11.022 pmcid: 23228924
Tham EB, Haykowsky MJ, Chow K et al (2013) Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson 15:48
pubmed: 23758789 pmcid: 3688348 doi: 10.1186/1532-429X-15-48
Choi BW, BergerHJ SPE et al (1983) Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 106:638–643
pubmed: 6613807 doi: 10.1016/0002-8703(83)90080-7 pmcid: 6613807
Schwartz RG, McKenzie WB, Alexander J et al (1987) Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82:1109–1118
pubmed: 3605130 doi: 10.1016/0002-9343(87)90212-9 pmcid: 3605130
Jiji RS, Kramer CM, Salerno M (2012) Non-invasive imaging andmonitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol 19:377–388
pubmed: 22351492 pmcid: 3314105 doi: 10.1007/s12350-012-9512-2
Bellenger NG, Burgess MI, Ray SG et al (2000) Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 21:1387–1396
pubmed: 10952828 doi: 10.1053/euhj.2000.2011 pmcid: 10952828
Carri’o IM, Estorch M, Bern’a L, L’opez-Pousa J, Tabernero J, Torres G (1995) Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 36:2044–2049
Estorch M, Carrió I, Martínez-Duncker D, Berná L, Torres G, Alonso C, Ojeda B (1993) Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J Clin Oncol 11:1264–1268
pubmed: 8315423 doi: 10.1200/JCO.1993.11.7.1264 pmcid: 8315423
Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 10:391–399
pubmed: 19341970 doi: 10.1016/S1470-2045(09)70042-7 pmcid: 19341970
de Korte MA, de Vries EG, Lub-de Hooge MN et al (2007)
pubmed: 17719768 doi: 10.1016/j.ejca.2007.06.024 pmcid: 17719768
Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG (2006) Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24:2276–2282
pubmed: 16710024 doi: 10.1200/JCO.2005.03.8448 pmcid: 16710024
Borde C, Kand P, Basu S (2012) Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: evidence of early chemotherapeutic cardiotoxicity? World J Radiol 4:220–223
pubmed: 22761982 pmcid: 3386534 doi: 10.4329/wjr.v4.i5.220
Sarocchi M, Bauckneht M, Arboscello E et al (2018) An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline. J Transl Med. 16(1):295
pubmed: 30359253 pmcid: 6202821 doi: 10.1186/s12967-018-1670-9
Laursen A, Elming M, Hasbak P et al (2018, 2018) Rubidium-82 positron emission tomography for detection of acute doxorubicininduced cardiac effects in lymphoma patients. J Nucl Cardiol. https://doi.org/10.1007/s12350-018-1458-6
Westermann D, Neumann JT, Sorensen NA, Blankenberg S (2017) High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol 14(8):472–483
pubmed: 28383022 doi: 10.1038/nrcardio.2017.48 pmcid: 28383022
Michel L, Rassaf T, Totzeck M (2018) Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 10(Suppl 35):S4282–S4295
pubmed: 30701097 pmcid: 6328390 doi: 10.21037/jtd.2018.08.15
Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN (2012) Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 35(7):443–450
pubmed: 22588943 pmcid: 6652695 doi: 10.1002/clc.22007
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, Group ESCSD (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119–177
pubmed: 28886621 doi: 10.1093/eurheartj/ehx393 pmcid: 28886621
Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AA, Cannegieter SC, Jukema JW, Umans VA, Schalij MJ, van Boven AJ (2013) Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 112(12):1867–1872
pubmed: 24063839 doi: 10.1016/j.amjcard.2013.08.019 pmcid: 24063839
Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–2754
pubmed: 15148277 doi: 10.1161/01.CIR.0000130926.51766.CC pmcid: 15148277
Cardinale D, Colombo A, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910–3916
pubmed: 20679614 doi: 10.1200/JCO.2009.27.3615 pmcid: 20679614
Ky B, Putt M, Sawaya H et al (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 63(8):809–816
pubmed: 24291281 doi: 10.1016/j.jacc.2013.10.061 pmcid: 24291281
Li-Ling Tan LL, Lyon AR (2018) Role of biomarkers in prediction of cardiotoxicity during cancer treatment. Curr Treat Options Cardiovasc Med 20:55
pubmed: 29923056 pmcid: 6008350 doi: 10.1007/s11936-018-0641-z
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC et al (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5:596–603
pubmed: 22744937 pmcid: 22744937 doi: 10.1161/CIRCIMAGING.112.973321
Wang YD, Chen SX, Ren LQ (2016) Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity. Oncol Lett 11(5):3483–3492
pubmed: 27123140 pmcid: 4840927 doi: 10.3892/ol.2016.4424
Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdiere C, Michon B, Schorin MA, Sallan SE (2012) Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 30(10):1042–1049
pubmed: 22370326 pmcid: 3341148 doi: 10.1200/JCO.2010.30.3404
Zhang C, Shi D, Yang P (2019) BNP as a potential biomarker for cardiac damage of breast cancer after radiotherapy: a meta-analysis. Medicine (Baltimore) 98(29):e16507
doi: 10.1097/MD.0000000000016507
Pavo N, Raderer M, Hulsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Kostler W, Zochbauer-Muller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R (2015) Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 101(23):1874–1880
pubmed: 26416836 doi: 10.1136/heartjnl-2015-307848 pmcid: 26416836
Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 55(3):213–220
pubmed: 20117401 doi: 10.1016/j.jacc.2009.03.095 pmcid: 20117401
Nakamae H, Tsumura K, Terada Y et al (2005) Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 104(11):2492–2498
pubmed: 16247790 doi: 10.1002/cncr.21478 pmcid: 16247790
Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 37(21):1671–1680
pubmed: 26903532 pmcid: 4887703 doi: 10.1093/eurheartj/ehw022
Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, Kalay N, Dikilitas M, Yarlioglues M, Karaca H, Berk V, Ardic I, Ergin A, Lam YY (2013) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int Cardiol. 167(5):2306–2310
doi: 10.1016/j.ijcard.2012.06.023
Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr et al (2018) Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 71(20):2281–2290
pubmed: 29540327 doi: 10.1016/j.jacc.2018.02.049 pmcid: 29540327
Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH (2016) Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol. 2(8):1030–1037
pubmed: 27348762 doi: 10.1001/jamaoncol.2016.1726 pmcid: 27348762
Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A (2015) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 17(1):81–89
pubmed: 25410653 doi: 10.1002/ejhf.196 pmcid: 25410653
Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH (2012) Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.J. Am Coll Cardiol. 60(23):2384–2390
doi: 10.1016/j.jacc.2012.07.067
Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 35(8):893–911
pubmed: 27918725 doi: 10.1200/JCO.2016.70.5400 pmcid: 27918725
Cardinale D, Ciceri F, Latini R et al (2018) Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 94:126–137
pubmed: 29567630 doi: 10.1016/j.ejca.2018.02.005 pmcid: 29567630
Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, Vetsch J, Frey E, Windsor R, LCM K, Levitt G (2019) Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. J Cancer Surviv (5):759–772

Auteurs

George Makavos (G)

2nd Department of Cardiology, "Attikon" Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Haidari, 12462, Athens, Greece. gmakavos@hotmail.com.

Ignatios Ikonomidis (I)

2nd Department of Cardiology, "Attikon" Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Haidari, 12462, Athens, Greece.

John Palios (J)

2nd Department of Cardiology, "Attikon" Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Haidari, 12462, Athens, Greece.

Angelos Rigopoulos (A)

Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strasse 40, 06120, Halle (Saale), Germany.

Konstantinos Katogiannis (K)

2nd Department of Cardiology, "Attikon" Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Haidari, 12462, Athens, Greece.

John Parissis (J)

2nd Department of Cardiology, "Attikon" Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Haidari, 12462, Athens, Greece.

Ioannis Paraskevaidis (I)

Department of Clinical Therapeutics, "Alexandra" Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Michel Noutsias (M)

Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strasse 40, 06120, Halle (Saale), Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Cardiac imaging in cardiotoxicity: a focus on...
questionsmedicales.fr › Phénomènes physiques › Rayonnement › Cardiotoxicité › Cardiac imaging in cardiotoxicity: a focus on...
questionsmedicales.fr › Diagnostic › Diagnostic précoce › Dépistage précoce du cancer › Cardiac imaging in cardiotoxicity: a focus on...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic cardiovasculaire › Tests de la fonction cardiaque › Échocardiographie › Cardiac imaging in cardiotoxicity: a focus on...
questionsmedicales.fr › Système cardiovasculaire › Coeur › Cardiac imaging in cardiotoxicity: a focus on...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Cardiac imaging in cardiotoxicity: a focus on...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cardiac imaging in cardiotoxicity: a focus on...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Dysfonction ventriculaire › Dysfonction ventriculaire gauche › Cardiac imaging in cardiotoxicity: a focus on...